InnoCan Pharma Corporation(INNPF)
USD --+0.00%
Reward48Moderate
Risk48Moderate
📊75%Data
Thin -12% profit margin · Revenue down 21% YoY
INNPF
+0.0 · +0.00%
USD · OTCQB
InnoCan Pharma Corporation | Consumer Defensive
Profitless Growth
Market Cap:24.56M
ℹ️
Reward Rating
48
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
48
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on INNPF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is InnoCan Pharma Corporation?

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally.

INNPF · Verdict

Moderate reward · moderate risk

INNPF's standout is volatility; cash flow and valuation weigh on the picture.

Based on 88% data coverage

INNPF · Verdict

What’s working & what to watch

Strengths 1

  • Volatility95/100

    Top decile vs peers

Watchouts 3

  • Cash flow14/100

    -5% free-cash-flow margin

  • Valuation30/100

    Below average

  • Profitability32/100

    -6% net margin · -33% ROE

Model-based scoring. For information only — not financial advice.

What is InnoCan Pharma Corporation?

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. The company is listed on the OTCQB in USA, operating in the Consumer Defensive sector, with a market capitalisation of 24.56M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (48)

The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorConsumer Defensive
Market Cap24.56M
P/E RatioN/A
Dividend YieldN/A
52 Week High14.26
52 Week Low0.1145
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding4M
No. of EmployeesN/A
IndustryHousehold & Personal Products
ExchangeOTCQB
Beta0.021
CurrencyUSD